Search results
Showing 151 to 200 of 3761 results for treatment
Evidence-based recommendations on rituximab for treating relapsed or refractory stage 3 or 4 follicular non-Hodgkin's lymphoma in adults.
Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had pemetrexed and cisplatin.
Evidence-based recommendations on removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment. This involves surgically removing ovarian tissue before a treatment for cancer or other medical condition that can damage the ovaries (gonadotoxic treatment) begins. The ovarian tissue is then frozen to be reimplanted after the gonadotoxic treatment is finished, to restore fertility.
View recommendations for HTG693Show all sections
Evidence-based recommendations on gefitinib (Iressa) for untreated locally advanced or metastatic non-small-cell lung cancer in adults.
Evidence-based recommendations on lenalidomide (Revlimid) for treating multiple myeloma in adults who have had at least 2 prior therapies.
Evidence-based recommendations on abemaciclib (Verzenios) with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence in adults.
Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis in adults.
Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
In development Reference number: GID-TA11774 Expected publication date: 30 September 2026
Endovenous laser treatment of the long saphenous vein (HTG26)
Evidence-based recommendations on endovenous laser treatment of the long saphenous vein. This involves using laser and heat to seal up the vein.
View recommendations for HTG26Show all sections
Sections for HTG26
Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.
Drug-eluting stents for the treatment of coronary artery disease (TA152)
Evidence-based recommendations on using drug-eluting stents in adults.
Evidence-based recommendations on cinacalcet (Mimpara) for treating secondary hyperparathyroidism in people with end-stage renal disease who are on dialysis.
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) (TA148)
NICE is unable to recommend the use in the NHS of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small-cell lung cancer (other than predominantly squamous cell histology) because no evidence submission was received from the manufacturer or sponsor of the technology.
Show all sections
Sections for TA148
Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
Evidence-based recommendations on blinatumomab (Blincyto) with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia in adults.
Radially emitting laser fibre treatment of an anal fistula (HTG505)
Evidence-based recommendations on radially emitting laser fibre treatment of an anal fistula in adults. This involves applying laser energy to the fistula.
View recommendations for HTG505Show all sections
Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy in adults.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.
This document contains advice to help you access treatments and care that NICE has recommended
Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.
View recommendations for TA223Show all sections
Laparoscopic helium plasma coagulation for the treatment of endometriosis (HTG112)
Evidence-based recommendations on laparoscopic helium plasma coagulation for the treatment of endometriosis. This involves a minimally invasive procedure used to vaporise endometrial deposits.
View recommendations for HTG112Show all sections
Sections for HTG112
In development Reference number: GID-TA10575 Expected publication date: TBC
Evidence-based recommendations on bevacizumab (Avastin), with other drugs, for treating metastatic colorectal cancer in adults.
Electrocautery cutting balloon treatment for pelviureteric junction obstruction (HTG205)
Evidence-based recommendations on electrocautery cutting balloon treatment for pelviureteric junction obstruction. This involves widening the renal pelvis by inserting a catheter with a balloon and wire into the urinary tract.
View recommendations for HTG205Show all sections
Sections for HTG205
Implanted vagus nerve stimulation for treatment-resistant depression (HTG551)
Evidence-based recommendations on vagus nerve stimulation for treatment-resistant depression in adults. This involves implanting an electrical stimulator under the skin of the chest and connecting it by wires to the vagus nerve.
View recommendations for HTG551Show all sections
MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor
In development Reference number: GID-IPG10441 Expected publication date: TBC
Percutaneous cementoplasty for palliative treatment of bony malignancies (HTG117)
Evidence-based recommendations on percutaneous cementoplasty for palliative treatment of bony malignancies. This involves injecting a special cement into the bone in order to stabilise it, reduce pain, or both.
View recommendations for HTG117Show all sections
Sections for HTG117
Evidence-based recommendations on olaparib (Lynparza) with bevacizumab (Avastin) for high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.
Atrial fibrillation: current treatment with anticoagulation (IND128)
This indicator covers the percentage of patients who are currently treated with anticoagulation drug therapy in those patients with atrial fibrillation with a record of a CHA2DS2-VASc score of 2 or more. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM82
This process guide explains how treatment option summaries for multiple guidelines were developed in an open, transparent, and timely way, with appropriate expert input
Breast reconstruction using lipomodelling after breast cancer treatment (HTG280)
Evidence-based recommendations on breast reconstruction using lipomodelling after breast cancer treatment. This involves taking fat from the abdomen or thighs and injecting it into the breast in the area of the deformity caused by surgery.
View recommendations for HTG280Show all sections
Sections for HTG280
Laparoscopic gastric plication for the treatment of severe obesity (HTG293)
Evidence-based recommendations on laparoscopic gastric plication for the treatment of morbid obesity. This involves folding the stomach in on itself and stitching it together to reduce its volume.
View recommendations for HTG293Show all sections
Sections for HTG293
Evidence-based recommendations on percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciatica. This involves delivering heat energy to the damaged disc annulus.
In development Reference number: GID-TA11694 Expected publication date: TBC
NICE is unable to recommend the use in the NHS of bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab or a rituximab-containing regimen. This is because Napp Pharmaceuticals did not provide an evidence submission.
Show all sections
Sections for TA206
This indicator covers the percentage of patients aged 15 years and over who are recorded as current smokers who have a record of an offer of support and treatment within the preceding 24 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM40
Non-rigid stabilisation techniques for the treatment of low back pain (HTG239)
Evidence-based recommendations on non-rigid stabilisation techniques for the treatment of low back pain. This involves joining the problem bones together using a non-rigid implant between 2 or more vertebrae.
View recommendations for HTG239Show all sections
Sections for HTG239
Evidence-based recommendations on percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain. This involves relieving low back pain by delivering heat energy to the damaged disc.
NICE is unable to make a recommendation on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy. This is because AstraZeneca did not provide an evidence submission.
Show all sections
Sections for TA750
Arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis (HTG148)
Evidence-based recommendations on arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis. This involves flushing the joint with fluid, which is introduced through small incisions in the knee.
View recommendations for HTG148Show all sections
Sections for HTG148
Evidence-based recommendations on erlotinib (Tarceva) for treating EGFR-TK-positive non-small-cell lung cancer in adults.
NICE has developed a medtech innovation briefing (MIB) on Fungitell for antifungal treatment stratification .
Evidence-based recommendations on lapatinib (Tyverb) and trastuzumab (Herceptin) for treating metastatic hormone receptor-positive breast cancer that overexpresses HER2 in adults.
Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..
Evidence-based recommendations on using thrombolytic drugs (alteplase [Actilyse], reteplase [Rapilysin], streptokinase [Streptase] and tenecteplase [Metalyse]) for treating acute myocardial infarction in adults.
Evidence-based recommendations on unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor in adults. This involves applying ultrasound to a specific area on 1 side of the brain (thalamus).
View recommendations for HTG474Show all sections